Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study

Alessandro Mantovani1 · Chiara Zusi1,2 · Alessandro Csermely1 · Gian Luca Salvagno3 · Antonio Colecchia4 · Giuseppe Lippi3 · Claudio Maffeis2 · Giovanni Targher1

Received: 18 April 2022 / Accepted: 29 June 2022 / Published online: 13 July 2022 © The Author(s) 2022

Abstract
Purpose Little is known about the association between plasma adiponectin levels and nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). We examined whether there is an association between lower plasma adiponectin levels and the presence/severity of NAFLD in people with T2DM.
Methods We cross-sectionally recruited 79 men with non-insulin-treated T2DM and no known liver diseases, who had consecutively attended our diabetes outpatient service over a 6-month period and who underwent both ultrasonography and Fibroscan-measured liver stiffness (LSM). Nine single nucleotide polymorphisms (PNPLA3 rs738409 and other genetic variants) associated with NAFLD were investigated.
Results Among the 79 participants included (mean age 67 ± 10 years, BMI 27.7 ± 4 kg/m²), 28 did not have NAFLD, 32 had steatosis alone, and 19 had NAFLD with coexisting significant fibrosis (LSM ≥ 7.0 kPa by Fibroscan®). Compared to those without NAFLD, patients with hepatic steatosis alone and those with hepatic steatosis and coexisting significant fibrosis had lower high-molecular-weight adiponectin levels (5.5 [IQR 2.3–7.6] vs. 2.4 [1.8–3.7] vs. 1.6 [1.0–2.9] µg/mL; p < 0.001). After adjustment for age, body mass index, insulin resistance, and the PNPLA3 rs738409 variant, lower plasma adiponectin levels were found to be associated with increased odds of both steatosis alone (adjusted-OD 2.44, 95% CI 1.04–5.56, p = 0.042) and NAFLD with coexisting significant fibrosis (adjusted-OR 3.84, 95% CI 1.23–10.0, p = 0.020). Similar findings were observed after adjustment for the other eight genotyped NAFLD-related polymorphisms.
Conclusion Lower plasma adiponectin levels are closely associated with the presence and severity of NAFLD in men with T2DM, pointing to a role of adiponectin in NAFLD development and progression.

Keywords Hypoadiponectinemia · Liver fibrosis · NAFLD · Nonalcoholic steatohepatitis · NASH · Type 2 diabetes

Introduction
In the last few years, there has been steadily increasing scientific interest in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) because of their growing burden on public health worldwide [1, 2]. NAFLD has reached epidemic proportions in most high-income countries, affecting up to a third of the general adult population [3, 4] and up to ~70% of patients with type 2 diabetes mellitus (T2DM) [5], as well as almost all patients with severe obesity [6].

Although the precise mechanisms involved in the development and progression of NAFLD remain to be fully elucidated, it has become increasingly clear that insulin resistance and low-grade inflammation are two key factors involved in
the pathophysiology of NAFLD [7]. Crosstalk between adipokines and proinflammatory cytokines may play a role in the development of this liver disease [8, 9]. Adiponectin is a hormone mainly produced by adipocytes, which circulates in three different isoforms (i.e., low-molecular-weight (LMW), middle-molecular-weight (MMW), and high-molecular-weight (HMW) adiponectin) in the bloodstream [8–10]. Specifically, circulating levels of adiponectin are closely and inversely associated with insulin resistance, excess body weight, and ectopic fat deposition [8, 9].

In recent years, many observational studies [11–16] and some meta-analyses [17] have reported that lower plasma adiponectin levels are significantly associated with the presence and severity of NAFLD, especially in patients without T2DM, thereby suggesting that hypoadiponectinemia might represent a risk factor for NAFLD. However, little information is available to date on the association between lower plasma adiponectin levels and the presence of NAFLD or NASH in patients with T2DM [18]. Nor, to our knowledge, are any data available assessing whether this association is at least partially mediated by coexistence of the rs738409 genetic variant in the patatin-like phospholipase domain-containing 3 (PNPLA3) gene or other genetic polymorphisms that confer greater susceptibility to NAFLD and NASH [19, 20].

Therefore, in this cross-sectional study, we examined the following: (i) whether there was an association between plasma adiponectin levels and the presence and severity of NAFLD (as detected by liver ultrasonography and vibration-controlled transient elastography [VCTE]) in ambulatory patients with established T2DM and (ii) whether this association could be, at least partly, mediated by the coexistence of the PNPLA3 rs738409 variant or other NAFLD-related genetic polymorphisms.

Methods
Patients

We studied 79 Caucasian male volunteers with non-insulin-treated T2DM who had consecutively attended our diabetes outpatient service over a period of 6 months (from January to June 2019) and who agreed to undergo both liver ultrasonography and VCTE for diagnosis and staging of NAFLD. The exclusion criteria of the study were as follows: (a) history of significant alcohol consumption (defined as > 20 g of alcohol per day) and other known causes of chronic liver diseases (e.g., virus, drugs, autoimmunity, and hemochromatosis); (b) cirrhosis, cancer, and end-stage kidney disease (defined as estimated GFR < 15 mL/min/1.73 m² or chronic dialysis); (c) chronic use of potentially hepatotoxic drugs; and (d) insulin treatment. Taking into account the technical limitations of VCTE, patients with free abdominal fluid or congestive heart failure were also excluded from the study. Most patients enrolled in this study have also been included in other published studies [21, 22].

Clinical and laboratory data

Body mass index (BMI) was measured as kilograms divided by the square of height in meters. Waist circumference was measured at the midpoint between the lowest rib and the iliac crest. Blood pressure was measured with a standard sphygmomanometer after the subject had been seated quietly for at least 5 min. Subjects were considered to have arterial hypertension if their blood pressure was ≥ 140/90 mmHg or if they were taking any antihypertensive agents.

Venous blood samples were collected in the morning after an overnight fast. Complete blood count, serum liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyltransferase [GGT]), glucose, lipids, and other biochemical blood parameters were measured using standard laboratory procedures at the Central Laboratory of Verona Hospital, Verona, Italy. Hemoglobin A1c (HbA1c) was measured using the high-performance liquid chromatography analyzer Tosoh-G7 (Tosoh Bioscience Inc., Tokyo, Japan). Fasting insulin concentrations were measured using a chemiluminescent immunoassay (LIAISON, DiaSorin, Saluggia, Italy). Homeostasis model assessment (HOMA-IR) score was used for estimating insulin resistance [23]. The measurement of plasma adiponectin concentration was performed in duplicate by using an automated two-step sandwich immunoassay method specific for high-molecular-weight adiponectin via chemiluminescent enzyme immunoassay technology (LumiPulse® G HMW-Adiponectin, Fujiirebio, Tokyo, Japan). The intra-assay and inter-assay coefficients of variation were < 2.5 and < 3.3%, respectively [21]. Glomerular filtration rate (e-GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [24].

The presence of ischemic heart disease was defined as a documented history of myocardial infarction, angina, or coronary revascularization procedures. The presence of diabetic retinopathy (diagnosed with fundoscopy after pupillary dilation) was also recorded.

Liver ultrasonography and VCTE

Liver ultrasonography and VCTE were performed by a single expert physician, who was blinded to participants’ clinical and biochemical details. Ultrasound liver images were obtained with the participant (in the fasting state) on the left side in a decubitus position, with their right arm stretched above the head after taking a deep breath. Hepatic steatosis was diagnosed by ultrasonography using
a 4-MHz probe (MyLab 70, Esaote Group, Genova, Italy) according to specific ultrasound characteristics, including diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intra-hepatic vessel borders and the diaphragm [22, 25, 26]. Radiological scoring systems (e.g., the Hamaguchi index) and semi-quantitative ultrasonographic indices of steatosis severity were not available in this study.

Liver stiffness measurement (LSM) was performed by VCTE using Fibroscan® (Echosens, Paris, France) and an M probe. We did not have the Fibroscan® XL probe for severely obese patients. The accuracy of the Fibroscan® M probe to identify significant liver fibrosis is excellent in patients with overweight or grade 1 obesity (BMI ≤ 35 kg/m²) [27]. In our study, only three patients had a BMI > 35 kg/m². Our Fibroscan® system was not equipped with the controlled attenuation parameter (CAP) technology for measuring hepatic steatosis. A trained physician performed LSM examinations in all patients after at least 8 h of fasting and after liver ultrasonography. Additional details of the examination procedures have been described elsewhere [25]. Briefly, each patient’s LSM was considered adequate if it included at least 10 valid measurements, with a success rate > 60% and measurement variability < 30% of the median [22]. The presence of significant hepatic fibrosis was defined as the presence of LSM ≥ 7 kPa (corresponding to Kleiner fibrosis stage ≥ F2 on liver histology) [22].

Genetic analysis

Genomic DNA was extracted from peripheral blood leukocytes using the QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany). In all participants, genotyping was carried out by predesigned TaqMan probes (Applied Biosystems, Foster City, CA, USA), according to the manufacturer’s protocol. Polymorphism genotyping was performed using 7900 HT Real-Time PCR (Applied Biosystems, USA). We genotyped the following nine genetic polymorphisms that have been associated with greater susceptibility to NAFLD or NASH: rs738409 in the patatin-like phospholipase domain-containing protein-3 (PNPLA3) gene, rs58542926 in the trans-membrane 6 superfamily member 2 (TM6SF2) gene, rs641738 in the membrane-bound O-acyltransferase domain containing 7 (MBOAT7) gene, rs1260326 in the glucokinase regulatory protein (GCKR) gene, rs2236212 in the elongation of very-long-chain fatty acids-like 2 (EVLOV2) gene, rs1535 in the fatty acid desaturase 2 (FADS2) gene, rs13412852 in the lipin 1 (LPIN1) gene, rs1800591 in the microsomal triglyceride transfer protein (MTTP) gene, and rs4880 in the superoxide dismutase 2 (SOD2) gene, respectively.

Statistical analysis

Owing to the exploratory design of the study, we did not perform an a priori sample size calculation. Continuous variables were expressed as means ± SD or medians and interquartile range (IQR) when indicated, while categorical variables were expressed as proportions. The chi-square test for categorical variables, the one-way analysis of variance for normally distributed continuous variables, and the Kruskal–Wallis test for non-normally distributed continuous variables (i.e., diabetes duration, triglycerides, insulin, HOMA-IR score, adiponectin, and Fibroscan-assessed LSM) were used to examine the intergroup differences in the main clinical and biochemical characteristics of participants, who were simultaneously stratified by the presence and severity of NAFLD (Table 1).

We tested the independent association between plasma adiponectin concentrations and the presence/severity of NAFLD by using unadjusted and adjusted multinomial logistic analyses. The dependent variable for these multinomial logistic regression models was the presence and severity of NAFLD, categorized as follows: patients without hepatic steatosis on ultrasound (reference group), patients with hepatic steatosis alone (group 1), and patients with hepatic steatosis and coexisting significant liver fibrosis, defined as LSM ≥ 7 kPa on VCTE (group 2). As depicted in Table 2, we performed four adjusted multinomial logistic regression models. Model 1 was adjusted for age, BMI (or waist circumference), and HOMA-IR score; model 2 was adjusted for age, BMI (or waist circumference), HOMA-IR score, and the PNPLA3 rs738409 variant; model 3 was controlled for age, BMI (or waist circumference), HOMA-IR score, and the TM6SF2 rs58542926 variant; and, finally, model 4 was controlled for age, BMI (or waist circumference), HOMA-IR score, and the MBOAT7 rs641738 variant. We also performed six other adjusted multinomial logistic models that adjusted for the same covariates of model 2 plus the other six genotyped NAFLD-related genetic variants (see supplementary material). The impact of each genetic variant on the severity of NAFLD was assessed using dominant genetic models. All the aforementioned multinomial logistic regression models were repeated even after excluding patients treated with pioglitazone, which is a glucose-lowering drug able to increase the circulating levels of adiponectin and improve liver fibrosis [15, 28], or those treated with SGLT2-inhibitors or GLP-1 receptor agonists, which are two glucose-lowering drugs also able to improve hepatic steatosis and increase plasma adiponectin levels. Covariates included in these logistic regression models were selected as potential confounding factors based on their significance in univariable analyses or based on their biological plausibility.

All statistical tests were two-sided, and a p value of < 0.05 (two tailed) was considered statistically significant.
Table 1  Clinical, biochemical, and genetic characteristics of men with type 2 diabetes, stratified by presence and severity of NAFLD (using both liver ultrasonography and Fibroscan®)

|                        | Patients without hepatic steatosis (n = 28) | Patients with hepatic steatosis alone (n = 32) | Patients with hepatic steatosis and significant fibrosis (n = 19) | p value  |
|------------------------|---------------------------------------------|------------------------------------------------|---------------------------------------------------------------|----------|
| Age (years)            | 71.3 ± 8                                    | 64.8 ± 8                                      | 62.8 ± 10                                                    | 0.002    |
| Weight (kg)            | 76.8 ± 14                                   | 86.9 ± 15                                    | 91.5 ± 10                                                    | 0.001    |
| BMI (kg/m²)            | 25.8 ± 4                                    | 28.2 ± 4                                     | 29.8 ± 4                                                     | 0.002    |
| Waist circumference (cm)| 97 ± 10                                     | 103 ± 13                                     | 108 ± 10                                                     | 0.004    |
| Diabetes duration (years)| 13.5 (6–22)                               | 10 (7–18)                                    | 9 (4–15)                                                     | 0.275    |
| Current smokers (%)    | 10.7                                        | 12.5                                         | 15.8                                                         | 0.913    |
| Systolic blood pressure (mmHg) | 131 ± 20                                 | 133 ± 20                                     | 131 ± 16                                                     | 0.863    |
| Diastolic blood pressure (mmHg) | 72 ± 12                                   | 77 ± 8                                       | 82 ± 9                                                       | 0.005    |
| Platelet count (× 100,000/mm³) | 221 ± 66                                  | 222 ± 52                                     | 234 ± 60                                                     | 0.743    |
| Fasting glucose (mmol/L) | 7.2 ± 1.8                                  | 7.1 ± 1.3                                    | 7.4 ± 1.6                                                    | 0.779    |
| Hemoglobin A1c (mmol/mol Hb) | 51.3 ± 8.7                                | 53.7 ± 6.2                                   | 53.1 ± 8.4                                                   | 0.475    |
| Fasting insulin (mU/L) | 4.1 (2.7–7.2)                              | 6.0 (3.8–9.1)                                | 9.6 (4.2–16.8)                                               | 0.001    |
| HOMA–IR score          | 1.3 (0.7–1.9)                               | 1.8 (1.1–2.8)                                | 3.2 (1.3–5.9)                                                | < 0.001  |
| Total cholesterol (mg/dL)| 163 ± 45                                   | 141 ± 35                                     | 149 ± 30                                                     | 0.083    |
| HDL cholesterol (mg/dL) | 51 ± 11                                    | 48 ± 16                                      | 43 ± 11                                                      | 0.167    |
| Triglycerides (mg/dL)  | 92 (69–144)                                 | 106 (89–138)                                 | 158 (124–209)                                               | 0.002    |
| AST (IU/L)             | 24 ± 5                                      | 27 ± 11                                      | 27 ± 8                                                       | 0.289    |
| ALT (IU/L)             | 13 ± 5                                      | 17 ± 8                                       | 18 ± 9                                                      | 0.022    |
| GGT (IU/L)             | 19 (14–29)                                  | 22 (15–34)                                   | 30 (17–50)                                                   | 0.064    |
| Albumin (g/dL)         | 48 ± 3                                      | 49 ± 2                                       | 48 ± 3                                                       | 0.197    |
| Creatinine (umol/L)    | 91.7 ± 27                                   | 81.2 ± 22                                   | 89.4 ± 17                                                   | 0.199    |
| e-GFRCKD-EPI (mL/min/1.73 m²) | 83.1 ± 28                               | 96.2 ± 29                                   | 83.3 ± 19                                                   | 0.107    |
| Hypertension (%)       | 85.7                                        | 75.0                                         | 79.0                                                        | 0.596    |
| Ischemic heart disease (%) | 14.3                                      | 12.5                                         | 21.1                                                        | 0.671    |
| Diabetic retinopathy, any degree (%) | 15.4                                    | 20.0                                         | 11.1                                                        | 0.788    |
| Metformin (%)          | 75.0                                        | 96.9                                         | 100                                                         | 0.005    |
| Sulfonylureas (%)      | 17.9                                        | 28.1                                         | 36.9                                                        | 0.320    |
| Pioglitazone (%)       | 17.9                                        | 15.6                                         | 10.5                                                        | 0.855    |
| DPP-4 inhibitors (%)   | 14.3                                        | 28.1                                         | 21.1                                                        | 0.448    |
| GLP-1 receptor analogues (%) | 21.4                                   | 28.1                                         | 31.6                                                        | 0.767    |
| SGLT-2 inhibitors (%)  | 3.6                                         | 21.9                                         | 21.1                                                        | 0.093    |
| Antiplatelet drugs (%) | 44.4                                        | 58.1                                         | 42.1                                                        | 0.500    |
| Beta-blockers (%)      | 40.7                                        | 22.6                                         | 36.8                                                        | 0.322    |
| ARB or ACE inhibitors (%) | 66.7                                 | 58.1                                         | 57.9                                                        | 0.798    |
| Calcium-channel blockers (%) | 25.9                                  | 25.8                                         | 36.9                                                        | 0.659    |
| Diuretics (%)          | 25.9                                        | 22.6                                         | 31.6                                                        | 0.758    |
| Statins (%)            | 85.7                                        | 83.9                                         | 68.4                                                        | 0.312    |
| HMW adiponectin (µg/mL)| 5.5 (2.3–7.6)                               | 2.4 (1.8–3.7)                                | 1.6 (1.0–2.9)                                               | < 0.001  |
| Fibroscan-assessed LSM (kPa) | 4.5 (3.7–5.3)                     | 5.5 (4.7–6.2)                                | 8.8 (7.9–11.8)                                              | ND       |

**PNPLA3 rs738409**

| CC (%) | 46.4 | 50.0 | 52.6 |
| CG (%) | 50.0 | 43.8 | 42.1 |
| GG (%) | 3.6  | 6.3  | 5.3  |

**TM6SF2 rs58542926**

| CC (%) | 89.3 | 84.4 | 94.7 |
| CT (%) | 10.7 | 15.6 | 5.3  |
| TT (%) | 0    | 0    | 0    |
of the 79 men with non-insulin-treated T2DM included in the study (mean age 67 ± 10 years, BMI 27.7 ± 4 kg/m², HbA1c 52 ± 6 mmol/mol), 28 (35.5%) did not have NAFLD on ultrasonography, 32 (40.5%) had hepatic steatosis alone, and 19 (24%) had NAFLD with coexisting significant fibrosis (i.e., LSM ≥ 7.0 kPa on Fibroscan®, respectively).

Table 1 shows the main clinical, biochemical, and genotypic characteristics of participants who were simultaneously stratified by the presence and severity of NAFLD. Compared with those without NAFLD, patients with NAFLD, regardless of the presence or absence of significant fibrosis, were more likely to be younger, centrally obese, and more insulin resistant (as reflected by a higher HOMA-IR score) and also had greater diastolic blood pressure and higher serum ALT and triglyceride concentrations. Notably, compared to those without NAFLD, patients with NAFLD had markedly higher molecular-weight adiponectin levels (5.5 [IQR 2.3–7.6] vs. 2.4 [1.8–3.7] µg/mL; p < 0.001 for trend). No significant intergroup differences were observed in terms of diabetes duration, smoking history, systolic blood pressure, glycemic control, total and HDL cholesterol, platelet count, AST, GGT, albumin, kidney function parameters, and comorbidities (such as prior ischemic heart disease and diabetic retinopathy), as well as the current use of lipid-lowering, anti-hypertensive, antiplatelet, or glucose-lowering agents (except for metformin use). Moreover, there were no significant intergroup differences in the distribution of the PNPLA3, TM6SF2, and MBOAT7 variants among the patient subgroups. No significant intergroup differences were also found in the other six genotyped NAFLD-related polymorphisms (data not shown).

Figure 1 shows that there was a significant inverse association between plasma adiponectin levels and Fibroscan-assessed LSM in the whole group of patients. The independent association between plasma adiponectin levels and the presence and severity of NAFLD is illustrated in Table 2. In the unadjusted regression model, lower plasma adiponectin levels were significantly associated with nearly threefold and sixfold odds of either hepatic steatosis alone or NAFLD with coexisting significant fibrosis. These results remained statistically significant after adjustment for age, BMI, and HOMA-IR score (model 1). The additional adjustment for either the PNPLA3 (model 2), TM6SF2 (model 3), or MBOAT7 (model 4) genetic variants did not substantially change the results. Almost identical results were also observed even when we included waist circumference as a covariate (instead of BMI), when we additionally adjusted for duration of diabetes, or when we excluded those with Fibroscan-assessed LSM ≥ 20 kPa (n = 2) (data not shown). Similar results were also observed when we excluded patients treated with pioglitazone (n = 13) (Supplementary Table 1), those treated with SGLT-2 inhibitors (n = 12) (Supplementary Table 2), or those treated with GLP-1 receptor agonists (n = 21) (Supplementary Table 3). However, in this latter case, the significance of the results was weaker in fully adjusted regression models; we believe that this is likely due to the smaller sample size available for this latter analysis (58 patients included). Finally, as reported in Supplementary Table 4, the further
The main findings of our cross-sectional study are as follows: (a) in Caucasian men with non-insulin-treated T2DM, lower plasma high-molecular-weight adiponectin levels were significantly associated with threefold and sixfold odds of either hepatic steatosis alone or NAFLD with coexisting significant fibrosis, and (b) these associations remained statistically significant even after adjusting for age, adiposity measures, duration of diabetes, HOMA-IR score, the PNPLA3 rs738409 variant, or other genetic variants associated with greater susceptibility of NAFLD and fibrosing NASH.

In a meta-analysis of 27 observational studies that reported data on 2243 individuals (1545 patients with NAFLD and 698 controls), Polyzos et al. reported that control subjects had significantly higher plasma adiponectin levels compared to patients with simple steatosis alone (random-effects weighted mean difference [WMD] \(3.0, 95\% \text{ CI} 1.57–4.43, I^2 = 80.4\%\)) or those with NASH (random-effects WMD \(4.70, 95\% \text{ CI} 3.71–5.78, I^2 = 84.1\%\)) [17]. By performing a meta-regression analysis, age, sex, BMI,
and pre-existing diabetes failed to account for the observed heterogeneity [17]. In another observational study, plasma adiponectin levels were significantly lower in patients with NAFLD than in those with viral hepatitis or other chronic liver diseases [29]. In a cross-sectional study including 84 Brazilian obese patients with T2DM and biopsy-proven NAFLD, Leite et al. reported that plasma adiponectin levels were lower in patients with NASH than in their counterparts without NASH [18]. Finally, in a recent systematic review and meta-analysis of 12 case–control studies, Zheng et al. reported that rs266729 and rs3774261 polymorphisms in the adiponectin gene were associated with a higher risk of having NAFLD among Asian, Chinese, and Caucasian populations [30].

Collectively, our findings confirm and extend the aforementioned observations, showing a strong association between lower plasma adiponectin levels and the presence and severity of NAFLD (as assessed with liver ultrasonography and Fibroscan®, which are the two most widely used diagnostic tools to non-invasively diagnose and stage NAFLD in clinical practice [31]) in Caucasian outpatients with non-insulin-treated T2DM. Some studies showed that NAFLD patients carrying the \( \text{PNPLA3} \) G/G genotype had lower plasma adiponectin levels compared to those with the \( \text{PNPLA3} \) C/C genotype [32], whereas others did not [14]. Notably, in our study, we showed for the first time that the inverse association between plasma adiponectin levels and the presence/severity of NAFLD remained statistically significant even after adjusting for the \( \text{PNPLA3} \) rs738409 variant or other less common NAFLD-related genetic polymorphisms. Although the results of our study do not have clear implications for clinical practice, they may be important for guiding future mechanistic and intervention studies. In fact, the evidence from this and other studies [11–16, 18] suggests a possible role of decreased adiponectin levels in the pathophysiology of NAFLD, thus underlining the need for future large-scale studies assessing the predictive as well as the therapeutic role of this adipokine in the spectrum of NAFLD. Additionally, these results may encourage the designing of diagnostic accuracy studies to examine whether plasma adiponectin levels may contribute (alone or in combination with other biomarkers) to the achievement of a non-invasive diagnosis of liver fibrosis.

To date, the role of adiponectin in the pathogenesis of NAFLD has not been fully elucidated. It is well known that adiponectin is one of the most important and abundant adipose-tissue-secreted adipokines [33]. Adipocytes secrete adiponectin into the bloodstream as three oligomeric complexes, including a low-molecular-weight (LMW) trimer, a medium-molecular-weight (MMW) hexamer, and a high-molecular-weight (HMW) multimer [10]. HMW adiponectin is the predominant isoform in circulation and has been identified as the most active biological isoform. HMW adiponectin exerts beneficial systemic metabolic and anti-inflammatory effects, as it promotes improvements in hepatic and systemic insulin sensitivity, glucose uptake, and lipid metabolism [10]. Adiponectin acts by binding and activating two different receptor isoforms, namely AdipoR1 and AdipoR2, expressed in skeletal muscle and the liver, among other tissues [34, 35]. Decreased plasma adiponectin levels are strongly associated with abdominal obesity, ectopic fat deposition, and greater insulin resistance [8, 9]. However, adiponectin may also signal in the liver, exerting a beneficial insulin-sensitizing effect [8, 9, 15]. Indeed, adiponectin regulates glucose and lipid metabolism by stimulating hepatic fatty acid oxidation and inhibiting hepatic fatty acid synthesis, mostly via the activation of the AMP-activated protein kinase [15]. Adiponectin may also attenuate liver fibrosis by inducing nitric oxide production of hepatic stellate cells that constitutively express both AdipoR1 and AdipoR2 [36]. Adiponectin also stimulates TIMP metalloproteinase inhibitor-1 (TIMP-1) secretion by hepatic stellate cells to retard their migration, thereby further contributing to the anti-fibrotic effect of adiponectin [37]. Overall, therefore, hypoadiponectinemia might promote the development of NAFLD and liver fibrosis [35, 38]. It is well known that glitazones (especially pioglitazone) have demonstrated promising results in randomized controlled trials for treatment of NASH [39]. Interestingly, parallel increases in plasma adiponectin levels and histological improvement of NASH were also observed in a systematic review of four randomized clinical trials, providing data on 187 patients with NASH treated up to 12 months [40]. Consequently, some authors have proposed that administration of adiponectin or an adiponectin analog (e.g., osmontin) might be an attractive pharmacological strategy for management of conditions characterized by adiponectin deficiency, such as NAFLD or...
NASH [8, 41]. Another potential therapeutic option would be the upregulation of endogenous adiponectin. Although the use of glitazones, such as rosiglitazone or pioglitazone, has been restricted due to moderate weight gain, peripheral fluid retention, and an increase in myocardial infarction risk (rosiglitazone), the non-thiazolidinedione, selective peroxisome proliferator-activated receptor-γ modulators, like INT131 besylate, could be promising candidates for randomized controlled trials with the potential to improve both glucose metabolism and NAFLD/NASH (while minimizing the side effects of full PPAR-γ agonists) [8, 42]. However, further research is needed to examine the therapeutic role of administration of adiponectin or an adiponectin analog in patients with NAFLD.

Our study has some limitations that should be mentioned. Firstly, the cross-sectional design of this single-center study limits our ability to establish temporal or causal associations between lower adiponectin levels and presence/severity of NAFLD. Secondly, the sample size of our study was small and was comprised of Caucasian men with metabolically well-controlled T2DM. Thus, these results cannot necessarily be extrapolated to other ethnic groups of patients, to women with T2DM (notably, the exploration of sex differences is today a priority of NAFLD research [43]), or to patients with uncontrolled glycemia. On the other hand, this latter limitation can represent a specific strength of our study in that it shows that lower adiponectin levels are associated with NAFLD and significant fibrosis in the absence of major changes in glycemia. Thirdly, we did not perform a liver biopsy or magnetic resonance elastography for staging liver fibrosis. Consequently, we were not able to compare the results of liver stiffness obtained by VCTE with histology data. However, both liver ultrasonography and VCTE are widely used for the diagnosis and staging of NAFLD in routine clinical practice [31]. In addition, a meta-analysis of 12 observational studies (published from January 2011 to February 2021) showed that conventional liver ultrasonography allows for reliable and accurate detection of ≥5% histologically defined hepatic steatosis (82% sensitivity and 80% specificity), as well as moderate-severe hepatic steatosis (85% sensitivity and 85% specificity), compared to liver histology [44].

Despite these limitations, our study has some important strengths, including the consecutive enrolment of the study population, its data completeness, and the adjustment for diabetes-related variables and other potential confounders, including a large panel of specific NAFLD-related genetic polymorphisms. In addition, the liver ultrasound and VCTE examinations were performed by a single trained physician, who was blinded to participants’ clinical and biochemical details, thereby eliminating both assessment bias and interobserver variability. Finally, we excluded patients with important comorbidities (for example, cirrhosis, advanced kidney disease, or cancer), deeming that including patients with such comorbidities might have confounded the interpretation of data.

In conclusion, our cross-sectional study shows that lower plasma adiponectin levels are closely associated with the presence and severity of NAFLD in men with T2DM. Notably, this association remained significant even after adjusting for age, adiposity measures, HOMA-IR score, the PNPLA3 genetic variant, or other NAFLD-related genetic polymorphisms that confer a greater susceptibility to NAFLD and NASH. Although our findings suggest a possible role of hypoadiponectinemia in the development and progression of NAFLD in patients with T2DM, larger studies are required to further corroborate these results in other patient cohorts and to more thoroughly understand the biological mechanisms underlying this association. We also believe that future studies should better elucidate the specific role of different isoforms of adiponectin in the pathophysiology of NAFLD, as well as the AdipoR1 and AdipoR2 signaling mechanisms involved in the development and progression of NAFLD.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s42000-022-00387-6.

Funding Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

Declarations

Ethics approval The protocol of the study was approved by the local Ethics Committee of the Hospital Trust of Verona (protocol number: CE 2004CESC), Verona, Italy. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.

Conflict of interest The authors declare no competing interests.

Informed consent Written informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice
guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–402.
2. Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357
3. Le MH, Yeo YH, Li X, et al. 2019 Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021.
4. Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399:61–116
5. Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71:793–801
6. Lonardo A, Mantovani A, Lugari S et al (2020) Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol 19:359–366
7. Mantovani A, Scorletti E, Mosca A et al (2020) Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 111:154170
8. Boutari C, Mantzoros CS (2020) Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 103:154028
9. Shahbalala SC, Djidla PV, Mabasa L et al (2020) The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacother 131:110785
10. Choi HM, Doss HM, Kim KS (2020) Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci 21:1219
11. Lian K, Feng YN, Li R et al (2020) Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease. J Clin Lab Anal 34:e23148
12. Kim YS, Lee SH, Park SG et al (2020) Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 103:154026
13. Mavilia MG, Wu GY (2021) Liver and serum adiponectin levels in non-alcoholic fatty liver disease. J Dig Dis 22:214–221
14. Marques V, Afonso MB, Bierig N et al (2021) Adiponectin, leptin, and IGF-1 are useful diagnostic and stratification biomarkers of NAFLD. Front Med (Lausanne) 8:683250
15. Gastroldelli A, Sabatini S, Carli F et al (2021) PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int 41:2659–2670
16. Zelber-Sagi S, Lotan R, Shlomi A et al (2012) Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 56:1145–1151
17. Polyzos SA, Toulis KA, Goulios DG et al (2011) Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 60:313–326
18. Leite NC, Salles GF, Cardoso CR et al (2013) Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 43:508–515
19. Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 68:268–279
20. Tavaglione F, Targher G, Valenti L et al (2020) Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 3:e00179
21. Mantovani A, Danese E, Salvagno GL et al (2021) Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. J Endocrinol Invest 44:547–555
22. Mantovani A, Turino T, Lando MG et al (2020) Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab 46:296–303
23. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495
24. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
25. Byrne CD, Patel J, Scorletti E et al (2018) Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ 362:k2734
26. Ballestrì S, Nascimbeni F, Baldelli E et al (2017) Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism 72:57–65
27. Puigvehi M, Broquetas T, Coll S et al (2017) Impact of anthropometric features on the applicability and accuracy of FibroScan((R)) (M and XL) in overweight/obese patients. J Gastroenterol Hepatol 32:1746–1753
28. Ishitq SM, Rashid H, Hussain Z et al (2019) Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease. Rev Endocr Metab Disord 20:253–261
29. Balmer ML, Joneli J, Schoepfer A et al (2010) Significance of serum adiponectin levels in patients with chronic liver disease. Clin Sci (Lond) 119:431–436
30. Zhong YT, Xiao TM, Wu CX et al (2022) Correlation of adiponectin gene polymorphisms rs266729 and rs3774261 with risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:798417
31. Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(1264–81):e4
32. Valenti L, Rametta R, Ruscica M et al (2012) The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterol 12:111
33. Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55:2319–2326
34. Yamauchi T, Nio Y, Makit T et al (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339
35. Xu H, Zhao Q, Song N et al (2020) AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis. Nat Commun 11:5807
36. Dong Z, Su L, Esmaili S et al (2015) Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J Mol Med (Berl) 93:1327–1339
37. Ramezani-Moghadam M, Wang J, Ho V et al (2015) Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion. J Biol Chem 290:5533–5542
38. Alzahrani B, Iseli T, Ramezani-Moghadam M et al (2018) The role of AdipoR1 and AdipoR2 in liver fibrosis. Biochim Biophys Acta Mol Basis Dis 1864:700–708
39. Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol
40. Polyzos SA, Mantzoros CS (2016) Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism 65:1297–1306
41. Ahmad A, Ali T, Kim MW et al (2019) Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARalpha signaling in ob/ob and db/db transgenic mouse models. Metabolism 90:31–43
42. DePaoli AM, Higgins LS, Henry RR et al (2014) Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37:1918–1923
43. Lonardo A, Nascimbeni F, Ballestri S et al (2019) Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 70:1457–1469
44. Ballestri S, Mantovani A, Byrne CD et al (2021) Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage 1:7

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.